Global Blood Therapeutics, Inc. (31)
Browse by Contract Category
Contracts
-
First Supplemental Indenture, dated as of October 5, 2022, between Global Blood Therapeutics, Inc. and U.S. Bank Trust Company, National Association, as trustee
(Filed With SEC on October 5, 2022)
-
Agreement and Plan of Merger, dated as of August 7, 2022, among Pfizer Inc., Ribeye Acquisition Corp. and Global Blood Therapeutics, Inc
(Filed With SEC on August 8, 2022)
-
Amendment No. 1 to License Agreement by and between the Registrant and Sanofi, dated April 15, 2022
(Filed With SEC on August 8, 2022)
-
Non-Employee Director Compensation Policy
(Filed With SEC on February 23, 2022)
-
Form of Capped Call Transaction Confirmation
(Filed With SEC on December 17, 2021)
-
License and Collaboration Agreement by and between the Registrant and Syros Pharmaceuticals, Inc., dated December 17, 2019
(Filed With SEC on February 26, 2020)
-
Amended and Restated Severance and Change in Control Policy
(Filed With SEC on February 23, 2022)
-
Amended and Restated U.S. Cash Incentive Bonus Plan
(Filed With SEC on February 23, 2022)
-
Indenture, dated as of December 17, 2021, between Global Blood Therapeutics, Inc. and U.S. Bank National Association, as trustee
(Filed With SEC on December 17, 2021)
-
Employment Offer Letter Agreement by and between the Registrant and Carrie Krehlik, dated June 15, 2021
(Filed With SEC on November 4, 2021)
-
Employment Offer Letter Agreement by and between the Registrant and Kim Smith-Whitley, M.D., dated November 24, 2020
(Filed With SEC on August 3, 2021)
-
License Agreement by and between the Company and Sanofi, dated March 12, 2021
(Filed With SEC on May 5, 2021)
-
Amended and Restated Cash Incentive Bonus Plan
(Filed With SEC on February 24, 2021)
-
Non-Employee Director Compensation Policy
(Filed With SEC on February 24, 2021)
-
Amended and Restated Severance and Change in Control Policy
(Filed With SEC on February 24, 2021)
-
Amended and Restated 2017 Inducement Equity Plan and forms of award agreements thereunder
(Filed With SEC on February 24, 2021)
-
Amended and Restated 2015 Stock Option and Incentive Plan and forms of award agreements thereunder
(Filed With SEC on February 24, 2021)
-
Amended and Restated Severance and Change in Control Policy (amended and restated through May 26, 2020)
(Filed With SEC on August 5, 2020)
-
Amended and Restated 2017 Inducement Equity Plan and forms of award agreements thereunder
(Filed With SEC on August 5, 2020)
-
Non-Employee Director Compensation Policy, as amended and restated on March 24, 2020
(Filed With SEC on May 6, 2020)
-
Amended and Restated 2015 Employee Stock Purchase Plan
(Filed With SEC on May 6, 2020)
-
Loan Agreement by and among the Registrant, BioPharma Credit PLC, and Biopharma Credit Investments V (Master) LP, dated December 17, 2019
(Filed With SEC on February 26, 2020)
-
Description of Securities
(Filed With SEC on February 26, 2020)
-
Cash Incentive Bonus Plan
(Filed With SEC on January 9, 2020)
-
Amended and Restated Severance and Change in Control Policy
(Filed With SEC on January 9, 2020)
-
Change in Control Policy
(Filed With SEC on November 7, 2019)
-
Employment Offer Letter by and between the Registrant and Eric Fink, dated June 17, 2019
(Filed With SEC on August 7, 2019)
-
Underwriting Agreement dated June 26, 2019 by and between Global Blood Therapeutics, Inc. and Cantor Fitzgerald & Co
(Filed With SEC on June 28, 2019)
-
Employment Offer Letter by and between the Registrant and Jung Choi, dated March 16, 2015
(Filed With SEC on May 10, 2019)
-
Employment Offer Letter by and between the Registrant and Brian Cathers, Ph.D., dated January 21, 2019
(Filed With SEC on February 27, 2019)
-
Non-Employee Director Compensation Policy
(Filed With SEC on February 27, 2019)
